|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
TWI687439B
(zh)
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
|
EP2877589B1
(en)
|
2012-07-26 |
2024-03-06 |
Momenta Pharmaceuticals, Inc. |
Glycoproteins with anti-inflammatory properties
|
|
US10450361B2
(en)
|
2013-03-15 |
2019-10-22 |
Momenta Pharmaceuticals, Inc. |
Methods related to CTLA4-Fc fusion proteins
|
|
WO2014186310A1
(en)
|
2013-05-13 |
2014-11-20 |
Momenta Pharmaceuticals, Inc. |
Methods for the treatment of neurodegeneration
|
|
RS59756B1
(sr)
|
2013-08-08 |
2020-02-28 |
Cytune Pharma |
Kombinovana farmaceutska kompozicija
|
|
PT3444271T
(pt)
|
2013-08-08 |
2022-01-05 |
Inst Nat Sante Rech Med |
Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
WO2015057622A1
(en)
|
2013-10-16 |
2015-04-23 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
|
EP3090066A4
(en)
*
|
2014-01-02 |
2017-08-30 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
JP6991857B2
(ja)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
EP3256165B1
(en)
*
|
2015-02-13 |
2021-07-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
|
JP6649941B2
(ja)
*
|
2015-02-16 |
2020-02-19 |
株式会社ファーマフーズ |
Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
|
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
NL2014935B1
(en)
*
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
|
AU2016317915B2
(en)
|
2015-09-01 |
2021-02-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
CN107406504B
(zh)
*
|
2015-11-19 |
2021-04-30 |
蔡则玲 |
Ctla-4抗体及其用途
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
ES2979210T3
(es)
*
|
2015-12-15 |
2024-09-24 |
Oncoc4 Inc |
Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス，インコーポレイティド |
ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
|
|
JP7069032B2
(ja)
|
2016-03-24 |
2022-05-17 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
がん免疫治療における胃腸の免疫関連有害事象の治療方法
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EA039322B1
(ru)
*
|
2016-04-15 |
2022-01-13 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
US20190365657A1
(en)
*
|
2016-08-17 |
2019-12-05 |
Orbis Health Solutions, Llc |
Tumor-targeting bead vectors and methods of using the same
|
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
|
WO2018035710A1
(en)
*
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN107815467B
(zh)
|
2016-08-31 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化基因改造动物模型的制备方法及应用
|
|
WO2018041121A1
(en)
|
2016-08-31 |
2018-03-08 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric ctla-4
|
|
CN107815468B
(zh)
|
2016-08-31 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化基因改造动物模型的制备方法及应用
|
|
JP7066696B2
(ja)
|
2016-10-11 |
2022-05-13 |
アジェナス インコーポレイテッド |
抗ｌａｇ－３抗体及びその使用方法
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
DK3551660T5
(da)
*
|
2016-12-07 |
2024-09-02 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
|
JP7165995B2
(ja)
*
|
2017-02-21 |
2022-11-07 |
アールイーエムディー バイオセラピューティクス，インコーポレイテッド |
細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
|
|
AU2018227428A1
(en)
*
|
2017-02-28 |
2019-10-17 |
Bristol-Myers Squibb Company |
Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to a vaccine
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
EP3597735A4
(en)
*
|
2017-03-15 |
2020-11-25 |
Suzhou Galaxy Biopharma, Co., Ltd. |
CTLA4 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USES THEREOF
|
|
CN116478289A
(zh)
*
|
2017-05-19 |
2023-07-25 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
|
JP7173993B2
(ja)
|
2017-05-19 |
2022-11-17 |
ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド |
細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
|
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
WO2019020807A1
(en)
*
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
|
JP2020528932A
(ja)
*
|
2017-07-28 |
2020-10-01 |
ジーン シグナル インターナショナル ソシエテ アノニム |
Ｃｄ９ｐ−１標的化抗体およびその使用
|
|
CA3073984A1
(en)
*
|
2017-09-21 |
2019-03-28 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-ctla4 antibodies and uses thereof
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
SG11202005692WA
(en)
*
|
2017-12-20 |
2020-07-29 |
Harbour Biomed Shanghai Co Ltd |
Antibodies binding ctla-4 and uses thereof
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
US12590133B2
(en)
|
2018-06-01 |
2026-03-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
CN110760002A
(zh)
|
2018-07-25 |
2020-02-07 |
南京金斯瑞生物科技有限公司 |
人源化抗人ctla4单克隆抗体及其制备方法和用途
|
|
CN120365435A
(zh)
|
2018-08-30 |
2025-07-25 |
免疫生物公司 |
单链嵌合多肽和多链嵌合多肽以及其用途
|
|
CN112996805A
(zh)
|
2018-08-30 |
2021-06-18 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
|
EP3843788A1
(en)
|
2018-08-30 |
2021-07-07 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
BR112021008060A2
(pt)
*
|
2018-10-31 |
2021-11-23 |
Bioatla Inc |
Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
|
|
KR20210108978A
(ko)
|
2018-12-21 |
2021-09-03 |
오제 이뮈노테라프틱스 |
이작용성 항-pd-1/il-7 분자
|
|
CA3122773A1
(en)
|
2018-12-26 |
2020-07-02 |
Xilio Development, Inc. |
Anti-ctla4 antibodies and methods of use thereof
|
|
SG11202106764YA
(en)
*
|
2018-12-27 |
2021-07-29 |
Gigagen Inc |
Anti-ctla-4 binding proteins and methods of use thereof
|
|
EP3914289A1
(en)
|
2019-01-23 |
2021-12-01 |
Massachusetts Institute of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
TWI869398B
(zh)
*
|
2019-05-10 |
2025-01-11 |
英商拜西克爾德有限公司 |
治療癌症之方法
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
JP7713393B2
(ja)
|
2019-06-21 |
2025-07-25 |
イミュニティーバイオ インコーポレイテッド |
多鎖キメラポリペプチドおよびその使用
|
|
WO2020263399A1
(en)
|
2019-06-26 |
2020-12-30 |
Massachusetts Institute Of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021009188A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies to human and canine ctla-4
|
|
CA3145345A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies against canine ctla-4
|
|
CN110467675B
(zh)
*
|
2019-09-19 |
2020-08-14 |
合源生物科技(天津)有限公司 |
一种ctla-4单克隆抗体6f1及其用于抗肿瘤的用途
|
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
UA128549C2
(uk)
|
2019-12-27 |
2024-08-07 |
Чугаі Сейяку Кабусікі Кайся |
Антитіло до ctla-4 та його застосування
|
|
CA3165927A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
KR20220140535A
(ko)
|
2020-02-11 |
2022-10-18 |
에이치씨더블유 바이올로직스, 인크. |
크로마토그래피 수지 및 이의 용도
|
|
US12115191B2
(en)
|
2020-02-11 |
2024-10-15 |
Immunitybio, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
EP4103599A1
(en)
|
2020-02-11 |
2022-12-21 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
US20230149560A1
(en)
|
2020-04-20 |
2023-05-18 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
CN115997008A
(zh)
|
2020-04-22 |
2023-04-21 |
艾欧凡斯生物治疗公司 |
协调用于患者特异性免疫疗法的细胞的制造的系统和方法
|
|
EP4143231A1
(en)
|
2020-04-29 |
2023-03-08 |
HCW Biologics, Inc. |
Anti-cd26 proteins and uses thereof
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
WO2021247003A1
(en)
|
2020-06-01 |
2021-12-09 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
EP4157460A1
(en)
|
2020-06-01 |
2023-04-05 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
WO2021250594A1
(en)
*
|
2020-06-11 |
2021-12-16 |
Nantbio, Inc. |
Anti-ctla4 monoclonal antibodies and chimeric antigen receptors
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
KR20230033719A
(ko)
*
|
2020-07-02 |
2023-03-08 |
기가젠, 인코포레이티드 |
항-ctla-4 결합 단백질 및 이의 사용 방법
|
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
WO2022169269A1
(ko)
*
|
2021-02-03 |
2022-08-11 |
주식회사 유틸렉스 |
항 ctla-4 항체 및 이의 용도
|
|
JP2024512029A
(ja)
|
2021-03-25 |
2024-03-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
MX2023011964A
(es)
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
AR126220A1
(es)
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
TWI879694B
(zh)
|
2021-06-25 |
2025-04-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
WO2023168363A1
(en)
|
2022-03-02 |
2023-09-07 |
HCW Biologics, Inc. |
Method of treating pancreatic cancer
|
|
EP4507711A1
(en)
|
2022-04-13 |
2025-02-19 |
ImmunityBio, Inc. |
Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
|
|
JP2025512401A
(ja)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
JP2025525886A
(ja)
|
2022-08-02 |
2025-08-07 |
オーエスイー・イミュノセラピューティクス |
Ｃｄ２８に対する多機能性分子
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
JP2025539816A
(ja)
|
2022-11-21 |
2025-12-09 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
EP4687991A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2026043906A1
(en)
|
2024-08-19 |
2026-02-26 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
US20260049118A1
(en)
|
2024-08-19 |
2026-02-19 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|